Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common stock, $0.001 par value per share
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
7.69M
-
Shares change
-
+33.5K
-
Total reported value, excl. options
-
$10.5M
-
Value change
-
-$2.02M
-
Put/Call ratio
-
0.18
-
Number of buys
-
22
-
Number of sells
-
-12
-
Price
-
$1.38
Significant Holders of LEAP THERAPEUTICS, INC. - Common stock, $0.001 par value per share (LPTX) as of Q3 2023
49 filings reported holding LPTX - LEAP THERAPEUTICS, INC. - Common stock, $0.001 par value per share as of Q3 2023.
LEAP THERAPEUTICS, INC. - Common stock, $0.001 par value per share (LPTX) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.69M shares
.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (1.17M shares), Rock Springs Capital Management LP (1.07M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (943K shares), CITADEL ADVISORS LLC (644K shares), Samsara BioCapital, LLC (602K shares), 683 Capital Management, LLC (490K shares), PRICE T ROWE ASSOCIATES INC /MD/ (444K shares), JANUS HENDERSON GROUP PLC (358K shares), Logos Global Management LP (354K shares), and ACUTA CAPITAL PARTNERS, LLC (354K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.